Search results for " GAS"

showing 10 items of 4643 documents

How to select early-stage cervical cancer patients still suitable for laparoscopic radical hysterectomy: a propensity-matched study

2020

Background: Recently, it was reported that minimally invasive surgery (MIS) has a negative impact on early-stage cervical cancer (ECC) patient survival. At the same time, advantages of MIS regarding quality of life and low rate of intra- and postoperative complications are well known. Therefore, it is essential to select patients who may benefit from MIS without worsening their oncologic outcomes. The aim of this study is to investigate which pathological factors could guide surgeons’ choice about the best approach in ECC. Patients and Methods: Patients with 2009 FIGO stage from IA1 with lymphovascular space invasion (LVSI) to IB1/IIA1 treated by open or laparoscopic surgery were judged eli…

AdultLaparoscopic surgerymedicine.medical_specialtymedicine.medical_treatmentlaparoscopyUterine Cervical NeoplasmsHysterectomyDisease-Free Survivalopen surgeryYoung Adult03 medical and health sciences0302 clinical medicineSurgical oncologymedicineHumansMinimally Invasive Surgical ProceduresRadical HysterectomyPropensity ScoreLaparoscopyGrading (tumors)minimally invasive surgeryAgedNeoplasm StagingRetrospective StudiesAged 80 and overCervical cancermedicine.diagnostic_testbusiness.industryParametrialCervical cancer; laparoscopy; minimally invasive surgery; open surgery; radical hysterectomy; tumor diameterHazard ratioMiddle Agedmedicine.diseaseSurgerySurvival RateTreatment OutcomeSettore MED/40 - GINECOLOGIA E OSTETRICIAItalyOncology030220 oncology & carcinogenesisradical hysterectomyCervical cancerFemale030211 gastroenterology & hepatologySurgerytumor diameterbusiness
researchProduct

Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015

2019

 The urgent need in HCV-infected patients with liver disease mandated the rapid implementation of IFN-free DAA combination therapies following their regulatory approval in 2014 and 2015 without full knowledge of the optimal combinations and regimens. Investigating the evolution of the DAA utilization patterns and treatment outcomes could provide learnings for future situations. This was an analysis of a prospective observational database from the German Hepatitis C Registry (DHC-R) covering a period from May 2014 to September 2015. Adult patients had evidence of chronic HCV GT1 or GT4 infection and were treated with an IFN-free combination regimen of simeprevir (SMV) + sofosbuvir (SOF) or o…

AdultLedipasvirSimeprevirmedicine.medical_specialtyDaclatasvirSustained Virologic ResponseSofosbuvirHepacivirusAntiviral Agents03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineHumansMedicineProspective StudiesRegistries030212 general & internal medicineFluorenesDasabuvirbusiness.industryGastroenterologyHepatitis C ChronicHepatitis COmbitasvirDrug CombinationsRegimenTreatment OutcomechemistryParitaprevirBenzimidazolesDrug Therapy Combination030211 gastroenterology & hepatologySofosbuvirbusinessmedicine.drugZeitschrift für Gastroenterologie
researchProduct

Fibrosis is not just fibrosis - basement membrane modelling and collagen metabolism differs between hepatitis B- and C-induced injury

2016

BACKGROUND: While morphological patterns differ, the molecular phenotype of liver fibrosis is considered a stereotypical response to chronic liver injury. However, with different cellular triggers and networks regulating fibrosis, the molecular responses of the injured liver may not be identical.AIM: To investigate whether differences in extracellular matrix (ECM) composition of the liver during fibrogenesis in two seemingly similar types of viral hepatitis could be reflected by differences in ECM turnover.METHODS: Utilising a cross-sectional design, we measured specific ECM protein fragments in plasma from 197 chronic hepatitis B (CHB) patients and 403 chronic hepatitis C (CHC) patients ma…

AdultLiver CirrhosisMale0301 basic medicinePathologymedicine.medical_specialtyInflammationMatrix metalloproteinaseBasement MembraneExtracellular matrix03 medical and health sciencesHepatitis B Chronic0302 clinical medicineFibrosisJournal ArticlemedicineHumansPharmacology (medical)Basement membraneExtracellular Matrix ProteinsHepatologybusiness.industryGastroenterologyHepatitis CHepatitis C ChronicMiddle AgedHepatitis Bmedicine.diseaseMatrix MetalloproteinasesExtracellular MatrixCross-Sectional Studies030104 developmental biologymedicine.anatomical_structureBiochemistryFemale030211 gastroenterology & hepatologyCollagenmedicine.symptomViral hepatitisbusinessBiomarkersAlimentary Pharmacology & Therapeutics
researchProduct

Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study

2018

Background & Aims The non-invasive identification of steatohepatitis (NASH) in patients with Non-Alcoholic Fatty Liver Disease is an unmet need in clinical practice. Index of NASH (ION) is a new tool for the prediction of NASH. We aimed to externally validate ION and to compare it with CK-18. Since necroinflammation precedes fibrosis, we also tested ION in combination with non-invasive tools for fibrosis. Methods We analysed data from 292 Italian patients (169 Southern cohort, and 123 Northern cohort) with an histological diagnosis of NAFLD. The ION, FIB-4 and NFS scores were calculated according to published algorithms. Serum cytokeratin18-Aspartate396 levels and liver stiffness (LS) by Fi…

AdultLiver CirrhosisMale0301 basic medicinemedicine.medical_specialtysteatohepatitisSeverity of Illness IndexGastroenterology03 medical and health sciencesLiver disease0302 clinical medicineNon-alcoholic Fatty Liver DiseaseFibrosisInternal medicineHumansMedicineIn patientProspective StudiesKeratin-18Hepatologymedicine.diagnostic_testbusiness.industryFatty liverExternal validationReproducibility of ResultsMiddle Agedmedicine.disease3. Good health030104 developmental biologyItalyLiverROC Curvenon-invasive markerLiver biopsyCohortElasticity Imaging TechniquesFemale030211 gastroenterology & hepatologySteatohepatitisfibrosibusinessAlgorithmsBiomarkersLiver International
researchProduct

Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis.

2015

Background and Aim. The best staining to evaluate liver fibrosis in liver hepatitis is still a debated topic. This study aimed to compare Masson’s trichrome (MT), Sirius Red (SR), and orcein stainings in evaluating liver fibrosis in chronic HCV hepatitis (CHC) with semiquantitative and quantitative methods (Collagen Proportionate Area (CPA) by Digital Image Analysis (DIA)) and correlate them with transient elastography (TE).Methods. Liver stiffness evaluation of 111 consecutive patients with CHC was performed by TE. Semiquantitative staging by Metavir score system and CPA by DIA were assessed on liver biopsy stained with MT, SR, and orcein.Results. MT, SR, and orcein staining showed concord…

AdultLiver CirrhosisMaleCancer ResearchPathologymedicine.medical_specialtyArticle SubjectAdolescentliver fibrosis elastography Digital Image Analysis liver biopsySettore MED/08 - Anatomia PatologicaPathology and Forensic Medicinechemistry.chemical_compoundYoung AdultTrichromeFibrosisImage Processing Computer-AssistedMedicineHumansOrceinSirius RedRC254-282AgedHepatitis ChronicHepatitisSettore MED/12 - Gastroenterologiamedicine.diagnostic_testQH573-671Staining and Labelingbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensCell BiologyGeneral MedicineMiddle Agedmedicine.diseaseStainingchemistryLiver biopsyMolecular MedicineElasticity Imaging TechniquesFemalebusinessTransient elastographyCytologyResearch ArticleAnalytical cellular pathology (Amsterdam)
researchProduct

Supportive and palliative care in people with cirrhosis: International systematic review of the perspective of patients, family members and health pr…

2018

Background & Aims People with cirrhosis have unmet needs, which could benefit from a palliative care approach. Developing effective services needs to be based on evidence from those with personal experience. This review aims to explore; patient and family perspectives of perceived needs including communication; health professionals' perspectives on delivery of care and improving palliative care between specialities. Methods A literature search was conducted in Medline, Embase and CINAHL using key words reporting on the perspectives of patients with liver cirrhosis (18 years and over), family members or health professionals on the provision of care in liver cirrhosis. Study quality was asses…

AdultLiver CirrhosisMaleHealth Knowledge Attitudes PracticePalliative careQuality Assurance Health Caremedia_common.quotation_subjectHealth PersonnelPsychological interventionMEDLINECINAHLDisease03 medical and health sciencesLiver disease0302 clinical medicineNursingHealth caremedicineHumansFamily030212 general & internal medicineQualitative Researchmedia_commonAgedQuality of Health CareHepatologybusiness.industryPalliative CareProfessional-Patient RelationsMiddle Agedmedicine.disease030211 gastroenterology & hepatologyFemalebusinessDelivery of Health CareSeriousnessJournal of hepatology
researchProduct

HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals

2017

Anecdotal reports suggest that patients with chronic hepatitis C virus (HCV) hepatitis and overt or occult hepatitis B virus (HBV) coinfection may reactivate HBV when HCV is suppressed or cleared by direct-acting antivirals (DAAs). We assessed the prevalence of overt or previous HBV coinfection and the risk of HBV reactivation in patients with HCV cirrhosis treated with DAAs. This was a retrospective cohort of 104 consecutive patients with HCV cirrhosis treated with DAAs. Serum HCV-RNA and HBV-DNA were tested at weeks 4, 8 and 12 of DAAs therapy and at week 12 of follow-up. At the start of DAAs, eight patients (7.7%) were HBsAg positive/HBeAg negative with undetectable HBV-DNA and low level…

AdultLiver CirrhosisMaleHepatitis B virusHBsAgCirrhosisHepacivirusHepacivirusmedicine.disease_causeAntiviral AgentsVirus03 medical and health sciencesHepatitis B Chronic0302 clinical medicineVirologymedicineHumansHBV-DNA reactivationnucleos(t)ide analogues therapyAgedRetrospective StudiesHepatitisHepatitis B virusHepatologybiologyCoinfectionbusiness.industryvirus diseasesRetrospective cohort studyHepatitis C ChronicMiddle Agedmedicine.diseasebiology.organism_classificationVirologyprevious HBV infectiondigestive system diseasesInfectious DiseasesHBV/HCV coinfection030220 oncology & carcinogenesisDNA ViralCoinfectionRNA ViralFemaleVirus Activation030211 gastroenterology & hepatologysustained virological responsebusiness
researchProduct

Early experiences from one of the first treatment programs for chronic hepatitis B in sub-Saharan Africa

2017

Treatment for chronic hepatitis B (CHB) is virtually absent in sub-Saharan Africa. Here we present early experiences from a pilot program for treatment of CHB in Ethiopia. Adults (≥18 years) with CHB were included in a cohort study at St. Paul’s Hospital Millennium Medical College, Addis Ababa, from February 2015. The baseline assessment included liver function tests, viral markers and transient elastography (Fibroscan 402, Echosense, France). Logistic regression models were used to identify predictors of fibrosis. Tenofovir disoproxil fumarate (TDF) was initiated based on the European Association for the Study of the Liver (EASL) criteria, with some modifications. The initial 300 patients …

AdultLiver CirrhosisMaleHepatitis B virusmedicine.medical_specialtyCirrhosisPilot ProjectsAntiviral therapyAntiviral Agentslcsh:Infectious and parasitic diseasesCohort StudiesYoung Adult03 medical and health sciencesHepatitis B Chronic0302 clinical medicinePregnancyInterquartile rangeInternal medicinemedicineHumanslcsh:RC109-216Hepatitis B e Antigens030212 general & internal medicinePregnancy Complications InfectiousTenofovirAIDS-Related Opportunistic Infectionsmedicine.diagnostic_testCoinfectionbusiness.industryAlanine TransaminaseMiddle AgedViral LoadHepatitis Bmedicine.diseaseResource-limited settingsInfectious DiseasesHBeAgAfricaImmunologyFemale030211 gastroenterology & hepatologyEthiopiaTransient elastographyLiver function testsbusinessViral loadBiomarkersResearch ArticleCohort study
researchProduct

The burden of HBV infection in HCV patients in Italy and the risk of reactivation under DAA therapy

2019

Background: There is increasing awareness of HBV reactivation in HCV-RNA-positive/HBV-coinfected patients with chronic liver disease (CLD) treated with oral direct-acting antivirals (DAAs). Aim: To provide figures on the prevalence of HBV markers in HCV-RNA-positive subjects in Italy, where these findings are lacking. Methods: All subjects aged ≥18 years with CLD consecutively referring to Italian liver units located throughout country were prospectively enrolled in two national surveys in 2001 and 2014. Results: The total number of HCV-RNA-positive cases was 6984; 356 (5.1%) subjects vaccinated against HBV were excluded. A total of 6628 cases were evaluated. The prevalence rates of HBsAg, …

AdultLiver CirrhosisMaleHepatitis B virusmedicine.medical_specialtyHBsAgCirrhosisHBV reactivationHbv markersHbv reactivationPrevalenceHbv vaccinationHepacivirusChronic liver diseaseAntiviral Agents03 medical and health sciences0302 clinical medicineInternal medicinePrevalencemedicineHumansHepatitis B AntibodiesReimbursementAgedHepatitis B Surface AntigensHepatologyCoinfectionbusiness.industryGastroenterologyHCV therapyvirus diseasesHepatitis C ChronicMiddle AgedHepatitis Bmedicine.diseaseChronic HCV infection; HBV reactivation; HBV/HCV coinfection; HCV therapydigestive system diseasesHBV/HCV coinfectionItalyChronic HCV infection030220 oncology & carcinogenesisDNA ViralFemaleVirus Activation030211 gastroenterology & hepatologybusiness
researchProduct

Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C.

2008

Iron overload and hepatitis virus C infection cause liver fibrosis in thalassemics. In a monocentric retrospective analysis of liver disease in a cohort of 191 transfusion-dependent thalassemics, in 126 patients who had undergone liver biopsy (mean age 17.2 years; 58 hepatitis virus C-RNA positive and 68 hepatitis virus C-RNA negative) the liver iron concentration (median 2.4 mg/gr dry liver weight) was closely related to serum ferritin levels (R = 0.58; p<0.0001). Male gender (OR 4.12) and serum hepatitis virus C-RNA positivity (OR 11.04) were independent risk factors for advanced liver fibrosis. The majority of hepatitis virus C-RNA negative patients with low iron load did not develop liv…

AdultLiver CirrhosisMaleLiver Iron ConcentrationCirrhosisIron OverloadAdolescentHepatitis C virusBiopsyHepacivirusSettore MED/08 - Anatomia Patologicamedicine.disease_causeCohort StudiesLiver diseasethalassemic iron chronic hepatitis CMedicineHumansRetrospective StudiesSettore MED/12 - Gastroenterologiamedicine.diagnostic_testbusiness.industryTransfusion ReactionHematologyHepatitis CHepatitis C ChronicViral Loadmedicine.diseaseLiverLiver biopsyImmunologySplenectomyThalassemiaFemalebusinessHepatic fibrosisViral loadHaematologica
researchProduct